APOE and Alzheimer disease: This predicts that ApoE4 carriers may experience insulin signaling impairment at a much earlier stage than ApoE3 carriers, albeit insulin signaling in both ApoE3 and ApoE4 carriers will eventually become similarly impaired in end stage post-mortem AD tissues10.